MedImmune in-licenses Pfizer's anti-CTLA-4 MAb globally
This article was originally published in Scrip
Executive Summary
MedImmune has in-licensed Pfizer's anti-CTLA-4 MAb known as tremelimumab and will develop it for a number of potential types of cancer, although details were not disclosed.